Therefore, we expected that HGF microencapsulation could provide stability to the growth factor and, as seen with IGF-1, its administration two days after MI induction (between the early inflammation and the later fibrosis) could be effective and would improve cardiac function. This evidence concerns the gene HGF and myocardial infarction.